Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial
Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial
复制标题
DOI：
10.1161/circulationaha.111.029165
复制
发表时间：
2011-09-06
期刊：
影响因子：
37.8
通讯作者：
Topol, Eric J.
中科院分区：
文献类型：
--
作者：
Price, Matthew J.;Angiolillo, Dominick J.;Topol, Eric J.
背景：在用VerifyNow P2Y12分析评估反应性：对血栓形成和安全性的影响(Gravitas)试验中，与标准剂量氯吡格雷相比，服用6个月的大剂量氯吡格雷并没有减少经皮冠状动脉介入治疗后治疗中血小板反应性(OTR)高的患者的心血管事件，根据VerifyNow P2Y12血小板功能测试，OTR>；=230个P2Y12反应单位。这项分析的目的是在试验过程中检查预后和OTR之间的关系。方法和结果-在经皮冠状动脉介入治疗后12-24小时和30+/-7天测量OTR。以OTR为时变协变量的Cox比例风险模型被用来确定OTR与心血管死亡、心肌梗死和支架血栓形成的主要终点之间的关联。在2800名登记的患者中，2796人(99.98%)具有可评估的血小板功能数据。Otr
Background-In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce cardiovascular events compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention, defined as OTR >= 230 P2Y12 reaction units according to the VerifyNow P2Y12 platelet function test. The aim of this analysis was to examine the relationship between outcomes and OTR over the course of the trial.Methods and Results-OTR was measured at 12 to 24 hours and 30 +/- 7 days after percutaneous coronary intervention. Cox proportional hazards models with OTR as a time-varying covariate were used to determine the association between OTR and the primary end point of cardiovascular death, myocardial infarction, and stent thrombosis. Of the 2800 enrolled patients, 2796 (99.98%) had evaluable platelet function data. OTR